WVE WAVE Life Sciences Ltd. gains 40% Dec 5, 2019

Preclinical biotech developing optimized RNA therapies for rare diseases.http://www.priceseries.com/trade/WVE-WAVE-Life-Sciences-Ltd-stock-gains-40-percent-a-Trade-Record-by-priceSeries-2019102520191205.html

URGN Urogen Pharma Ltd. gains 26% Dec 5, 2019

N/Ahttp://www.priceseries.com/trade/URGN-Urogen-Pharma-Ltd-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2019110820191205.html

REPH Recro Pharma, Inc. gains 57% Dec 5, 2019

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.http://www.priceseries.com/trade/REPH-Recro-Pharma-Inc-stock-gains-57-percent-a-Trade-Record-by-priceSeries-2019101520191205.html

MNK Mallinckrodt plc gains 17% Dec 5, 2019

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company's Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs. This segment offers Acthar, an injectable drug for various indications, such as neurology, rheumatology, nephrology, and pulmonology; Ofirmev, an intravenous formulation of acetaminophen for pain management; Inomax for inhalation; Therakos, an immunotherapy treatment platform; and Exalgo, a form of hydromorphone. It is also developing StrataGraft, a full-thickness product for severe burns and other complex skin defects. Its Specialty Generics segment provides specialty generic pharmaceuticals and active pharmaceutical ingredients (APIs) consisting of hydrocodone and hydrocodone-containing tablets; oxycodone and oxycodone-containing tablets; methylphenidate HCl extended-release tablets; and other controlled substances, including acetaminophen products. The company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. It distributes its branded and generic products through independent channels, including wholesale drug distributors, specialty pharmaceutical distributors, retail pharmacy chains, hospital networks, ambulatory surgical centers, and governmental agencies; and APIs directly or through distributors to other pharmaceutical companies. Mallinckrodt public limited company is based in Chesterfield, the United Kingdom.http://www.priceseries.com/trade/MNK-Mallinckrodt-plc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019112020191205.html

LN Line Corp gains 23% Dec 5, 2019

LINE Corporation develops and provides platform for mobile messaging and communication services, content distribution, and advertising in Japan and internationally. The company offers LINE, a cross-platform messenger application that enables users to communicate through free instant messaging, and voice and video calls, as well as serves as a smart portal to its other applications and services. It also provides communication and content sales and advertising services through the LINE platform; and advertising services are through LINE advertising, livedoor blog, and NAVER Matome Web portals. The company was formerly known as NHN Japan Corporation and changed its name to LINE Corporation in April 2013. The company was incorporated in 2000 and is based in Tokyo, Japan. LINE Corporation operates as a subsidiary of Naver Corporation.http://www.priceseries.com/trade/LN-Line-Corp-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2019110620191205.html

HSKA Heska Corp. gains 24% Dec 5, 2019

Heska Corporation develops, manufactures, and markets advanced veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. It operates through two segments, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and IV pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus Chewable Tablets for the preventive treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels. The Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and independent third-party distributors, as well as trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.http://www.priceseries.com/trade/HSKA-Heska-Corp-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2019102820191205.html

FOLD Amicus Therapeutics, Inc. gains 15% Dec 5, 2019

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.http://www.priceseries.com/trade/FOLD-Amicus-Therapeutics-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019110720191205.html

EYEG Eyegate Pharmaceuticals, Inc. gains 73% Dec 5, 2019

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. In addition, the company is developing Eyegate II drug delivery system. It has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.http://www.priceseries.com/trade/EYEG-Eyegate-Pharmaceuticals-Inc-stock-gains-73-percent-a-Trade-Record-by-priceSeries-2019110820191205.html

ESPR Esperion Therapeutics, Inc. gains 20% Dec 5, 2019

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.http://www.priceseries.com/trade/ESPR-Esperion-Therapeutics-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2019111520191205.html

CLVS Clovis Oncology, Inc. gains 149% Dec 5, 2019

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.http://www.priceseries.com/trade/CLVS-Clovis-Oncology-Inc-stock-gains-149-percent-a-Trade-Record-by-priceSeries-2019110720191205.html